Hologic (HOLX) Stock Price, News & Analysis

Company Overview

Hologic, Inc. (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions. A landmark transaction was the 2012 acquisition of Gen-Probe, which expanded the company’s leadership in molecular diagnostics and infectious disease testing. Over the years, Hologic has invested heavily in research and development, bringing advances such as rapid COVID-19 molecular tests and minimally invasive surgical technologies to market.

The company serves customers in more than 100 countries across North America, Europe, Latin America, Asia-Pacific and the Middle East. Its products are distributed to hospitals, diagnostic laboratories, imaging centers and physician offices, supported by manufacturing facilities and regional offices around the world. Through partnerships with health systems and public health agencies, Hologic’s diagnostic platforms play a critical role in early disease detection and population health screening programs.

Hologic is led by President and Chief Executive Officer Jan Verstreken, who has overseen the company’s strategic initiatives since 2022. Under his leadership, Hologic continues to prioritize innovation in women’s health and expand its global footprint, with ongoing efforts to streamline operations, strengthen supply chains and accelerate development of next-generation diagnostic and imaging technologies.

Key Stats

• Today's Range: $63.75 to $64.76
• 50-Day Range: $63.26 to $68.98
• 52-Week Range: $51.90 to $84.39
• Volume: 1.28 million shs
• Average Volume: 1.33 million shs
• Market Capitalization: $14.19 billion
• P/E Ratio: 26.47
• Dividend Yield: N/A
• Price Target: $78.00
• Consensus Rating: Moderate Buy

Hologic Stock Analysis - MarketRank™

Hologic scored higher than 99% of companies evaluated by MarketBeat, and ranked 24th out of 960 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Hologic has received a consensus rating of Moderate Buy. The company's average rating score is 2.59, and is based on 8 buy ratings, 8 hold ratings, and no sell ratings.

Upside Potential

Hologic has a consensus price target of $78.00, representing about 22.3% upside from its current price of $63.80.

Amount of Analyst Coverage

Hologic has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 7.94%

Earnings Growth

Earnings for Hologic are expected to grow by 7.94% in the coming year, from $4.28 to $4.62 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Hologic is 15.53, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 280.39.

Price to Earnings Ratio vs. Sector

The P/E ratio of Hologic is 15.53, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 74.93.

Price to Earnings Growth Ratio

Hologic has a PEG Ratio of 2.34. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Hologic has a P/B Ratio of 2.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.42% of the float of Hologic has been sold short.

Short Interest Ratio / Days to Cover

Hologic has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Hologic has recently decreased by 14.99%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Hologic does not currently pay a dividend.

Dividend Growth

Hologic does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -1.51

Percentage of Shares Shorted

1.42% of the float of Hologic has been sold short.

Short Interest Ratio / Days to Cover

Hologic has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Hologic has recently decreased by 14.99%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 4.1 / 5
• News Sentiment: 1.31

News Sentiment

Hologic has a news sentiment score of 1.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.94 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 26 news articles for Hologic this week, compared to 18 articles on an average week.

Search Interest

6 people have searched for HOLX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

2 people have added Hologic to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Hologic insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.88% of the stock of Hologic is held by insiders.

Percentage Held by Institutions

94.73% of the stock of Hologic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HOLX Stock Analysis - Frequently Asked Questions

How have HOLX shares performed this year?

Hologic's stock was trading at $72.09 at the beginning of 2025. Since then, HOLX shares have decreased by 11.5% and is now trading at $63.80.

How were Hologic's earnings last quarter?

Hologic, Inc. (NASDAQ:HOLX) posted its earnings results on Wednesday, July, 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. Hologic's revenue for the quarter was up 1.2% compared to the same quarter last year.
Read the conference call transcript.

Does Hologic have any subsidiaries?

Hologic subsidiaries include Bolder Surgical, Mobidiag Oy, Diagenode SA, Biotheranostics Inc, Somatex Medical Technologies GmbH, Acessa Health, Health Beacons Inc, and others.

Who are Hologic's major shareholders?

Top institutional shareholders of Hologic include Vanguard Group Inc. (12.05%), The Manufacturers Life Insurance Company (4.96%), State Street Corp (4.54%) and Invesco Ltd. (3.75%). Insiders that own company stock include Stephen P Macmillan, John M Griffin, Karleen Marie Oberton, Scott T Garrett, Christiana Stamoulis, Essex D Mitchell, Benjamin Jordan Cohn, Martin D Madaus, Brandon Schnittker and Charles J Dockendorff.
View institutional ownership trends.

How do I buy shares of Hologic?

Shares of HOLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Hologic own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Hologic investors own include American Water Works (AWK), Waste Connections (WCN), Humana (HUM), DiamondRock Hospitality (DRH), The RMR Group (RMR), AU Optronics (AUOTY) and Voyager Therapeutics (VYGR).

Company Calendar

• Last Earnings: 7/30/2025
• Today: 9/15/2025
• Fiscal Year End: 9/30/2025
• Next Earnings (Estimated): 11/03/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:HOLX
• CIK: 859737
• Web: www.hologic.com
• Phone: (508) 263-2900
• Fax: 781-890-8031
• Employees: 7,063
• Year Founded: 1985

Price Target and Rating

• Average Price Target for Hologic: $78.00
• High Price Target: $94.00
• Low Price Target: $68.00
• Potential Upside/Downside: +22.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.59
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.41
• Trailing P/E Ratio: 26.47
• Forward P/E Ratio: 14.91
• P/E Growth: 2.34
• Net Income: $789.50 million
• Net Margins: 13.79%
• Pretax Margin: 16.73%
• Return on Equity: 19.69%
• Return on Assets: 10.82%

Debt

• Debt-to-Equity Ratio: 0.52
• Current Ratio: 3.55
• Quick Ratio: 2.81

Sales & Book Value

• Annual Sales: $4.04 billion
• Price / Sales: 3.51
• Cash Flow: $5.44 per share
• Price / Cash Flow: 11.72
• Book Value: $22.09 per share
• Price / Book: 2.89

Miscellaneous

• Outstanding Shares: 222,419,000
• Free Float: 218,238,000
• Market Cap: $14.19 billion
• Optionable: Optionable
• Beta: 0.57